rs55770810
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
rs55770810
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
We identified a founder mutation (4153delA, 5382insC or C61G) in 6% of 235 unselected cases of breast cancer and in 19% of 43 unselected cases of ovarian cancer.
|
20345474 |
2010 |
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p < 0.01).
|
20569256 |
2010 |
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
The risk for breast cancer was 42% higher among first degree relatives of carriers of the C61G missense mutation compared to other mutations (HR = 1.42; p = 0.10) and the risk for ovarian cancer was lower than average (OR = 0.26; p = 0.03).
|
16227521 |
2006 |
rs28897672
|
|
|
0.730 |
GeneticVariation |
UNIPROT |
|
|
|
rs1800726
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1800751
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1800757
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs273900729
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80187739
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80356898
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80356993
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80357233
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80357438
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80357462
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80357474
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80357669
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80357828
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs1799950
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Further characterisation of rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
|
29298688 |
2018 |
rs1799950
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We resequenced BRCA1 and BRCA2 in 194 women with a familial history of breast and/or ovarian cancer and identified nine possibly biologically relevant polymorphisms (BRCA1 Gln356Arg, Pro871Leu, Glu1038Gly, Ser1613Gly, and Met1652Ile.
|
19661094 |
2009 |
rs1799950
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The rare form of the Q356R polymorphism was significantly ( P = 0.03) associated with a family history of ovarian cancer, suggesting that this polymorphism may influence ovarian cancer risk.
|
10196379 |
1999 |
rs748876625
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This finding indicates the necessity of searching for 300T>G mutation in families with a single diagnosis of ovarian cancer in family.
|
22395474 |
2012 |
rs786203319
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |
rs80357750
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |